Oxaliplatin Treatment Alters Systemic Immune Responses

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Oxaliplatin is a platinum-based chemotherapy agent with known antitumor activity.
• Unlike immunosuppressive agents, oxaliplatin may stimulate immune responses via damage-associated molecular patterns (DAMPs).
• The systemic effects of oxaliplatin on immune cell populations and cytokine profiles are not fully understood.

Purpose of the Study:

• To investigate the impact of oxaliplatin on splenic immune cells (T cells, B cells, macrophages) and associated cytokines.
• To analyze changes in thymocyte subsets (CD4+, CD8+) following oxaliplatin treatment.
• To evaluate the effects of oxaliplatin on bone marrow hematopoietic stem and progenitor cells.

Main Methods:

• Male BALB/c mice were treated with oxaliplatin (3mg/kg/d) or sterile water for two weeks.
• Flow cytometry was used to assess leukocyte populations in spleen, thymus, and bone marrow.
• RT-PCR was employed to analyze gene expression of inflammation-associated factors in the spleen.

Main Results:

• Oxaliplatin reduced spleen size and cellularity but increased proportions of CD4+, CD8+, and Treg cells.
• Selective cytotoxicity was observed for B cells; macrophages were unaffected. TNF-α expression was elevated.
• Gene expression of splenic cytokines and chemokines was altered. Thymocyte populations showed an increase in CD8+ single-positive and activated CD8+ T cells.
• Bone marrow hematopoietic progenitor cells remained normal post-treatment.

Conclusions:

• Oxaliplatin treatment does not lead to systemic immunosuppression.
• Oxaliplatin demonstrates potential to induce beneficial immune responses against tumors.